An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics

09 Feb 2021 According to The Russian Direct Investment Fund media release, Sputnik V vaccine against coronavirus has been approved by Drug Regulatory Authority of Pakistan (DRAP) based on the results of the clinical trials of Sputnik V in Russia
23 Sep 2020 New trial record
16 Sep 2020 According to The Russian Direct Investment Fund (RDIF) media release, results from this phase I/II study were published in The Lancet Journal (as of 4th Sep 2020).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com